A Phase 3 interventional study of Fenfluramine and Placebo in CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure and Epileptic Spasm, sponsored by Zogenix, Inc.. Active, not recruiting at 46 sites in 14 countries. Open to participants aged 1 Year to 35 Years. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Epilepsy, Tonic-Clonic with a site in United States — 1 open to participants now, 2 under way, 2 of them phase 3. Epilepsy, Tonic-Clonic · United States.
Among the 11 studies in Epilepsy, Tonic-Clonic with a site in United States, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 3 in phase 3, and was the 9th registered.
23 studies on the registry are indexed under Epilepsy, Tonic-Clonic; 3 are open to participants now.
Browse Epilepsy, Tonic-Clonic studies →1 of the 11 studies in Epilepsy, Tonic-Clonic with a site in United States is open now. Recruiting first, the newest first:
Praxis Precision Medicines · Sites in United States, Brazil, Germany and 3 more countries
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Epilepsy, Tonic-Clonic studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 1 Year to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is close to the median of 94 across 20 interventional studies indexed under Epilepsy, Tonic-Clonic.
Median enrollment 134 across the 10 interventional studies, 1,278 across the 1 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 10 most frequent:
This study is registered under Zogenix, Inc., one of the names counted as UCB S.A.. Under that name alone:
Zogenix, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
UCB S.A. has 3 studies filed under Epilepsy, Tonic-Clonic — fewer than ten, so there is no comparison to draw.
1 of the studies in Epilepsy, Tonic-Clonic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05064878Phase 3Zogenix, Inc.A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder. | 2027-11-08 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Epilepsy, Tonic-Clonic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 Study to examine the efficacy and safety of ZX008 in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).
This is an up to 3-part multicenter study: a double-blind, placebo-controlled part (Part 1) which includes Baseline Period (4 weeks), Titration Period (2 weeks), Maintenance Period (12 weeks) and Transition Period (2 weeks), followed by up to 2 open-label extension (OLE) parts: Part 2 of 54 weeks [Treatment Period (52 weeks), Taper Period (2 weeks)] and Part 3, i.e., OLE1 and OLE2, respectively, with the addition of the second OLE part (Part 3/OLE2) only for participants who will continue on fenfluramine and have no alternative treatment access from another source (e.g., a managed access program [MAP]). Participants can remain in Part 3 until MAP access or approval of fenfluramine (ZX008) has been obtained from regulatory authorities for CDD in the participant's country of residence, or until the investigational product development for CDD is stopped by the Sponsor, whichever comes first. Participants who discontinue early from Part 1, Part 2, or Part 3 will attend a Cardiac Follow-Up Visit 6 months after their last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Fenfluramine (hydrochloride) 0.8 mg/kg/day will be administered twice a day (BID) in equally divided doses; maximum of 30 mg/day, (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, \[maximum of 20 mg/day\]) with or without food.
Drug: Fenfluramine
Part 1: Matching fenfluramine (hydrochloride) placebo will be administered twice a day (BID) in equally divided doses with or without food.
Drug: Placebo
Part 2 and Part 3: Open-label fenfluramine (hydrochloride) will be administered using a flexible dosing regimen, up to fenfluramine 0.8 mg/kg/day; maximum dose: 30 mg/day (subjects taking concomitant stiripentol will receive 0.5 mg/kg/day, \[maximum of 20 mg/day\]). Fenfluramine (hydrochloride) will be administered twice a day (BID) in equally divided doses with or without food.
Drug: Fenfluramine
Fenfluramine is supplied as an oral aqueous solution of fenfluramine hydrochloride.
Also known as: FINTEPLA, ZX008, fenfluramine HCl, fenfluramine hydrochloride
Matching fenfluramine (hydrochloride) placebo is supplied as an oral solution.
Percentage Change from Baseline in Countable Motor Seizure Frequency (CMSF) (Part 1)
The median percentage change from the Baseline in monthly (per 28 days) CMSF during the combined Titration and Maintenance Periods with the fenfluramine (ZX008) 0.8 mg/kg/day group compared with the placebo group will be reported.
Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) (Part 2)
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment Emergent Adverse Events (TEAEs) are defined as any AEs reported on or after the first dose of study medication.
Time frame: Up to OLE1 Treatment Period Post-Dose Safety Follow-up Visit 17 (up to 70 weeks)
Percentage of Participants With Abnormal Physical Examination Findings (Part 2)
Abnormal findings of physical exam that is considered clinically significant by Principal Investigator (PI).
Time frame: Up to End of Treatment (EoT)/Early Termination (ET) Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Percentage of Participants With Abnormal Neurological Examination Findings (Part 2)
Abnormal findings of neurological exam that is considered clinically significant by PI.
Time frame: Up to EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Percentage of Participants with Positive Response to Self-harm Question (Part 2)
Time frame: OLE1 Treatment Period Day 1 to OLE1 Treatment Period Post-Dose Safety Follow-up Visit 17 (up to 70 weeks)
Percentage of Participants with Increase in Valvular Regurgitation from Baseline (except absent to trace) (Part 2)
Valvular regurgitation will be assessed using a 2-dimensional (2-D) Color Doppler Echocardiography (ECHO).
Time frame: Baseline (28 days), Cardiac Follow-up Visit 18 (up to 96 weeks)
Percentage of Participants with Pulmonary Arterial Hypertension (PASP > 35 mmHg) at any Time During Treatment on Repeat Testing (Part 2)
Time frame: OLE1 Treatment Period Day 1 to EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Change from Baseline in Laboratory Parameters (Hematology) (Part 2)
Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Change from Baseline in Laboratory Parameters (Hormones) (Part 2)
Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Change from Baseline in Laboratory parameters (Chemistry) (Part 2)
Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Change from Baseline in Laboratory Parameters (Urinalysis) (Part 2)
Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Change from Baseline in Vital Signs (Blood pressure) (Part 2)
Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Change from Baseline in Vital Signs (Heart rate) (Part 2)
Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Change from Baseline in Vital Signs (Temperature) (Part 2)
Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Change from Baseline in Vital Signs (Respiratory rate) (Part 2)
Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Change from Baseline in Body Weight (Part 2)
Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Change from Baseline in Tanner Staging (Part 2)
Time frame: Baseline (28 days), EoT/ET Visit 16 of OLE1 Treatment Period (up to 68 weeks)
Percentage of Participants with TEAEs (Part 3)
An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. Treatment Emergent Adverse Events are defined as any AEs reported on or after the first dose of study medication.
Time frame: Up to OLE2 Period Post-Dose Safety Follow-up (up to 200 weeks)
Change from Baseline in Height (Part 3)
Time frame: Baseline (28 days), OLE2 Period EoT/ET Visit 23 (up to 198 weeks)
Change from Baseline in Body Weight (Part 3)
Time frame: Baseline (28 days), OLE2 Period EoT/ET Visit 23 (up to 198 weeks)
Percentage of Participants with Increase in Valvular Regurgitation from Baseline (except absent to trace) (Part 3)
Valvular regurgitation will be assessed using a 2 D Color Doppler ECHO.
Time frame: Baseline (28 days), Cardiac Follow-up Visit (up to 295 weeks)
Percentage of Participants with Pulmonary Arterial Hypertension (PASP > 35 mmHg) at any Time During Treatment on Repeat Testing (Part 3)
Time frame: OLE2 Period Day 1 to EoT/ET Visit 23 of OLE2 Period (up to 198 weeks)
Percentage of Participants Who Achieve a ≥ 50% Reduction from Baseline in CMSF (Part 1)
The percentage of participants who achieve a ≥ 50% reduction from Baseline in CMSF during T+M periods, in the fenfluramine 0.8 mg/kg/day group compared with the placebo group.
Time frame: Baseline (28 days), Combined T+M Periods (14 weeks)
Percentage of Participants with a Clinical Global Impression-Improvement (CGI-I) Rating of 'Much Improved' or 'Very Much Improved' as Assessed by Investigator (Part 1)
The percentage of participants who achieve a CGI-I rating of much or very much improved as assessed by the Investigator at the end of T+M periods, in the fenfluramine 0.8 mg/kg group compared with the placebo group. The CGI-I rating scale permits a global evaluation of the participant's improvement over time. The severity of a participant's condition is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse) as follows: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse.
Time frame: At the end of the combined T+M Periods (14 weeks)
Percentage Change From Baseline in Monthly Generalized Tonic-Clonic (GTC) Seizure Frequency (Part 1)
The median percentage change from Baseline in monthly GTC seizure frequency during T+M periods, in the fenfluramine 0.8 mg/kg/day group compared with the placebo group.
Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)
Categorized Percentage Change in Seizures from Baseline in CMSF (Part 1)
The categorized median percentage change in seizures from the Baseline in monthly (per 28 days) CMSF during the combined T+ M periods will be presented in the following categories: no reduction or worsening, ≥25%, ≥75%, or 100% reduction.
Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)
Percentage of Participants who Achieve "Near Seizure Freedom" (Part 1)
The percentage of participants who achieve near seizure freedom, defined as 0 or 1 seizures, during T+M, in the fenfluramine 0.8 mg/kg/day group compared with the placebo group.
Time frame: Combined T+M Periods (14 weeks)
Percentage of Participants with a CGI-I Rating of 'Much Improved' or 'Very Much Improved' as Assessed by the Parent/Caregiver (Part 1)
The percentage of participants who achieve a CGI-I rating of much or very much improved as assessed by the by the parent/caregiver at the end of T+M periods, in the fenfluramine 0.8 mg/kg group compared with the placebo group.
Time frame: At the end of the combined T+M Periods (14 weeks)
Percentage of Participants with Improvement (Minimal, Much or Very Much Improved) on the CGI-I Rating as Assessed, Independently, by the Investigator (Part 1)
The percentage of participants who achieve a CGI-I rating of minimal, much or very much improved as assessed, independently, by the Investigator at the end of T+M periods, in the fenfluramine 0.8 mg/kg group compared with the placebo group.
Time frame: At the end of the combined T+M Periods (14 weeks)
Percentage of Participants with Improvement (Minimal, Much or Very Much Improved) on the CGI-I Rating as Assessed, Independently, by the Parent/Caregiver (Part 1)
The percentage of participants who achieve a CGI-I rating of minimal, much or very much improved as assessed, independently, by the parent/caregiver at the end of T+M periods, in the fenfluramine 0.8 mg/kg group compared with the placebo group.
Time frame: At the end of the combined T+M Periods (14 weeks)
Percentage Change from Baseline in the Monthly Frequency of all Seizures (Part 1)
The percentage change from the Baseline in the monthly (per 28 days) frequency of all seizures during the combined T+M period.
Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)
Change from Baseline in the Monthly Frequency of Countable Motor Seizure (CMS)-free Days (Part 1)
The change from the Baseline in the monthly (per 28 days) frequency of CMS-free days during the combined T+M periods.
Time frame: Baseline (28 days), Combined Titration and Maintenance (T+M) Periods (14 weeks)
Percentage of Participants with TEAEs (Part 1)
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. A TEAEs was defined as any adverse events with a start date/time on or after dosing of the study medication and up to end of the maintenance period (14 weeks) inclusive after dosing of the study medication.
Time frame: From Day of first dose to the End of the Maintenance Periods (up to 14 weeks)
Percentage of Participants With Abnormal Physical Examination Findings (Part 1)
Time frame: Baseline, Visit 6 (Day 43), Visit 7 (Day 71), Visit 8 (Day 99)
Percentage of Participants With Abnormal Neurological Examination Findings (Part 1)
Time frame: Baseline, Visit 6 (Day 43), Visit 8 (Day 99)
Percentage of Participants with Positive Response to Self-harm question (Part 1)
Time frame: Baseline, Visit 5 (Day 15), Visit 6 (Day 43), Visit 7 (Day 71), Visit 8 (Day 99)
Percentage of Participants with Increase in Valvular Regurgitation from Baseline (except absent to trace) (Part 1)
Valvular regurgitation will be assessed using a 2-D Color Doppler ECHO.
Time frame: From Day of first dose to the End of the Maintenance Period (up to 14 weeks)
Percentage of Participants with Pulmonary Arterial Hypertension (PASP > 35 mmHg) at any Time During Treatment on Repeat Testing (Part 1)
The safety and tolerability of fenfluramine (ZX008) will be assessed in pediatric and adult participants with CDD.
Time frame: From Day of first dose to the End of the Maintenance Period (up to 14 weeks)
Change from Baseline in Laboratory parameters (Hematology) (Part 1)
Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)
Change from Baseline in Laboratory parameters (Hormones) (Part 1)
Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)
Change from Baseline in Laboratory parameters (Chemistry) (Part 1)
Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)
Change from Baseline in Laboratory Parameters (Urinalysis) (Part 1)
Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)
Change from Baseline in Vital signs (Blood pressure) (Part 1)
Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)
Change from Baseline in Vital signs (Heart rate) (Part 1)
Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)
Change from Baseline in Vital signs (Temperature) (Part 1)
Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)
Change from Baseline in Vital signs (Respiratory rate) (Part 1)
Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)
Change from Baseline in Body Weight (Part 1)
Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)
Change from Baseline in Tanner Staging (Part 1)
Time frame: Baseline (28 days), end of the combined Titration and Maintenance (T+M) Periods (Day 99)
Percentage Change from Baseline in CMSF (Part 2)
The median percentage change from the Baseline in monthly (per 28 days) CMSF during the OLE Treatment Period.
Time frame: Baseline (28 days), OLE1 Treatment Period (up to 52 weeks)
Categorized Percentage Change in Seizures from Baseline in CMSF (Part 2)
The categorized percentage change in seizures from the Baseline in monthly (per 28 days) CMSF during OLE Treatment Period will be presented in the following categories: no reduction or worsening, ≥25%, ≥50%, ≥75%, or 100% reduction.
Time frame: Baseline (28 days), OLE1 Treatment Period (up to 52 weeks)
Percentage of Participants who Achieve "Near Seizure Freedom" (Part 2)
The percentage of participants who achieve near seizure freedom, defined as 0 or 1 seizures, during the OLE Treatment Period.
Time frame: OLE1 Treatment Period (up to 52 weeks)
Percentage of Participants with a CGI-I Rating of 'Much or Very Much Improved' as Assessed by the Investigator (Part 2)
The percentage of participants who achieve a CGI-I rating of much or very much improved as assessed by the Investigator at the OLE Treatment Period.
Time frame: At the End of the OLE1 Treatment Period (up to 52 weeks)
Percentage of Participants with a CGI-I Rating of 'Much or Very Much Improved' as Assessed by the Parent/Caregiver (Part 2)
The percentage of participants who achieve a CGI-I rating of much or very much improved as assessed by the parent/caregiver at the OLE Treatment Period.
Time frame: At the End of the OLE1 Treatment Period (up to 52 weeks)
Percentage of Participants with Improvement (Minimal, Much or Very Much Improved) on the CGI-I Rating as Assessed, Independently, by the Investigator (Part 2)
The percentage of participants who achieve a CGI-I rating of minimal, much or very much improved as assessed by the Investigator at the OLE Treatment Period.
Time frame: At the End of the OLE1 Treatment Period (up to 52 weeks)
Percentage of Participants with Improvement (Minimal, Much or Very Much Improved) on the CGI-I Rating as Assessed by the Parent/Caregiver (Part 2)
The percentage of participants who achieve a CGI-I rating of minimal, much or very much improved as assessed by the parent/caregiver at the OLE Treatment Period.
Time frame: At the End of the OLE1 Treatment Period (up to 52 weeks)
Percentage Change from Baseline in Monthly GTC Seizure Frequency (Part 2)
The median percentage change from baseline in monthly GTC seizure frequency during OLE Treatment Period.
Time frame: Baseline (28 days), OLE1 Treatment Period (up to 52 weeks)
Change from Baseline in the Monthly Frequency of CMS-free Days (Part 2)
The change from the Baseline in the monthly (per 28 days) frequency of CMS-free days during the OLE Treatment Period.
Time frame: Baseline (28 days), OLE1 Treatment Period (up to 52 weeks)
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
No publications or documents are linked to this record.
Started Mar 2022 (actual). Primary completion is estimated for Nov 2027, 68 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenfluramine